Cisplatin: all 1,652 studies that test it

Page 1 of 17. Open to participants first (223), then studies with results posted, then the rest; newest registration first within each.

• Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping PillsNot yet recruitingNCT07885462Phase 4
• PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingNCT07877584Phase 3
• A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingNCT07876817Phase 4
• Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingNCT07876154Phase 2
• Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicable
• This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.Not yet recruitingNCT07846358Phase 1/2
• Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingNCT07831993Phase 2
• Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid MalignanciesNot yet recruitingNCT07782346Phase 1
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
• A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingNCT07778368Phase 2
• Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCCNot yet recruitingNCT07776340Phase 2
• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.RecruitingNCT07739654Phase 3
• Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNot yet recruitingNCT07709585Phase 2
• A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaNot yet recruitingNCT07632235Phase 1/2
• Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingNCT07628062Phase 2
• Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07570849Phase 2
• Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533305Phase 2
• Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell CarcinomaRecruitingNCT07497607Phase 2
• Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung CancerNot yet recruitingNCT07495098Phase 1
• Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2
• Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal CarcinomatosisRecruitingNCT07475286Phase 2
• Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCCRecruitingNCT07452601Phase 2
• Cosiporfin Sodium for Injection Photodynamic TherapyRecruitingNCT07398339Phase 2
• Intralesional Chemotherapy (IC): Cisplatin + EpinephrineRecruitingNCT07392580Phase 2
• Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract CancerRecruitingNCT07392541Phase 1/2
• Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaRecruitingNCT07389057Not applicable
• Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCEnrolling by invitationNCT07353294Phase 1
• Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07349225Phase 2
• Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2
• A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Phase 1/2
• PDT For Induction Therapy For Head And Neck CancerRecruitingNCT07214987Phase 2
• Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder CancerNot yet recruitingNCT07184021Phase 2
• Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull BaseNot yet recruitingNCT07145931Phase 2
• An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal RecurrenceEnrolling by invitationNCT07139951Phase 2
• Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell CarcinomaRecruitingNCT07125755Phase 3
• Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT TrialRecruitingNCT07121595Phase 2
• Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.RecruitingNCT07121322Phase 2
• Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer PatientsRecruitingNCT07119996Phase 1
• Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaRecruitingNCT07076212Phase 2
• A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Not applicable
• Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingNCT07003815Phase 2
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
• Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06956716Phase 1/2
• Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical CancerRecruitingNCT06942416Phase 2
• Toripalimab With Chemotherapy for Sinus CancerRecruitingNCT06940180Phase 2
• Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial CarcinomaNot yet recruitingNCT06927128Phase 2
• Neoadjuvant Radiotherapy for Locally Advanced Unresectable ThymomaRecruitingNCT06924619Phase 2
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast CancerRecruitingNCT06900647Phase 1
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
• A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
• HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06858735Phase 2
• A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2
• Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLCRecruitingNCT06838208Phase 2
• A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2
• Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer OrganoidsEnrolling by invitationNCT06786780Phase 2
• Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingNCT06772623Phase 1/2
• Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06764355Phase 2
• Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCCRecruitingNCT06752798Phase 2
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06728618Phase 2
• Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic CholangiocarcinomaRecruitingNCT06721286Phase 2
• Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid CancerNot yet recruitingNCT06713057Phase 2
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
• The Minimalist Trial-2RecruitingNCT06702033Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular CarcinomaRecruitingNCT06632717Phase 2
• A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicable
• Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Phase 2
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
• Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCANot yet recruitingNCT06569225Phase 2
• Neoadjuvant Therapy in Cervical CancerRecruitingNCT06558682Not applicable
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
• CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract CancersRecruitingNCT06548412Phase 1/2
• Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingNCT06532539Phase 2
• Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT06459687Phase 3
• A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerRecruitingNCT06457503Phase 4
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingNCT06446388Phase 2
• Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal CancerRecruitingNCT06445114Phase 2
• Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.Not yet recruitingNCT06426056Phase 2
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT06423326Phase 2
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2
• Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical CancerRecruitingNCT06391190Phase 1/2
• Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingNCT06387056Phase 2
• Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingNCT06372626Phase 1/2
• A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingNCT06364904Phase 3
• Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerRecruitingNCT06357598Phase 4
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
• Hypofractionated RadiochemotherapyRecruitingNCT06331468Phase 2
• Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerRecruitingNCT06323460Phase 2
• SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal CarcinomaRecruitingNCT06323239Phase 2
• The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.Not yet recruitingNCT06295094Phase 2
• Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical CancerRecruitingNCT06289751Phase 2
• Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract CancerRecruitingNCT06280508Phase 2
• Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard ChemotherapyNot yet recruitingNCT06268327Phase 2/3

← Cisplatin overview